Roche and Qritive Partner to Revolutionize Global Cancer Diagnostics with AI
Curated by THEOUTPOST
On Thu, 12 Sept, 4:05 PM UTC
2 Sources
2 Sources
[1]
Roche and Singapore's Qritive for global cancer diagnostics with AI (OTCQX:RHHBY)
Qritive - digital pathology and AI company headquartered in Singapore collaborates with Roche (OTCQX:RHHBY) to advance cancer diagnostics and treatment and accelerate adoption of AI by pathologists. With Qritive's AI-powered solutions fully integrated with Roche (OTCQX:RHHBY) navify Digital Pathology platform, pathologists can leverage AI technology to diagnose cancer more accurately and efficiently, leading to reduced time to treatment and enhanced patient outcomes. More on Roche Holding Roche: Why I'm Not Concerned About Slight Sell-Off On Weight Loss Drug Safety Data Roche: A Long-Term Bottom May Have Been Struck (Technical Analysis) Roche Holding AG 2024 Q2 - Results - Earnings Call Presentation Roche falls while Novo, Lilly gain on weight-loss drug report UNICEF issues emergency tender to secure mpox vaccines
[2]
Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI
SINGAPORE, Sept. 12, 2024 /PRNewswire/ -- Qritive, a leading digital pathology and AI company headquartered in Singapore, is proud to announce its collaboration with Roche, one of the largest diagnostics and life sciences companies in the world. This collaboration represents a significant milestone to advance cancer diagnostics and treatment and accelerate adoption of AI by pathologists. With Qritive's AI-powered solutions fully integrated with Roche navify® Digital Pathology platform, pathologists can leverage AI technology to diagnose cancer more accurately and efficiently, leading to reduced time to treatment and enhanced patient outcomes. These clinically validated AI modules, designed for colon, prostate, breast, and gastric cancers, analyze whole slide images to identify and grade tumor with precision. These tools have been shown to improve pathology reporting time by up to 10-fold and reduce the risk of misdiagnosis dramatically. As Bruno Occhipinti, CEO of Qritive, puts it, "we are truly excited to see how the integration of our AI-powered solutions within the highly performing Roche navify® Digital Pathology platform will augment pathologists' performance, enabling affordable and accurate diagnostics at scale." Qritive's collaboration with Roche reinforces its commitment to empowering pathologists globally with state-of-the-art AI-powered solutions and alleviating the pressure on the healthcare system. By bringing its innovative AI-based pathology solutions to a broader audience, Qritive continues to play a pivotal role in the future of cancer diagnostics. For more information about Qritive and its AI-powered solutions, please visit www.qritive.com or contact info@qritive.com. About Qritive: Headquartered in Singapore, with operations in the US and India, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis and improving health outcomes. Qritive leverages deep learning technology to support the interpretation of pathology tests for time and resource-strapped pathologists, enabling faster diagnosis and reducing time to treatment for patients. Qritive is dedicated to empowering healthcare professionals across the globe with AI-powered solutions to operate collaboratively at the peak of their performance despite complexity and distance. View original content to download multimedia:https://www.prnewswire.com/news-releases/qritive-joins-forces-with-roche-to-redefine-global-cancer-diagnostics-with-ai-302245356.html SOURCE Qritive Pte. Ltd. Market News and Data brought to you by Benzinga APIs
Share
Share
Copy Link
Swiss pharmaceutical giant Roche collaborates with Singapore-based AI company Qritive to enhance cancer diagnostics worldwide using artificial intelligence, aiming to improve accuracy and efficiency in pathology.
Groundbreaking Partnership in Cancer Diagnostics
In a significant move that promises to reshape the landscape of cancer diagnostics, Swiss pharmaceutical behemoth Roche has joined forces with Qritive, a Singapore-based artificial intelligence (AI) company. This collaboration aims to leverage AI technology to enhance the accuracy and efficiency of cancer diagnosis on a global scale 1.
The Power of AI in Pathology
Qritive's AI-powered platform is set to be integrated with Roche's digital pathology solutions, creating a synergy that could potentially transform the field of pathology. The AI algorithms developed by Qritive are designed to assist pathologists in analyzing tissue samples more quickly and accurately, potentially leading to earlier and more precise cancer diagnoses 2.
Global Reach and Impact
The partnership between Roche and Qritive is not limited to a single market but has a global focus. By combining Roche's extensive international presence with Qritive's innovative AI technology, the collaboration aims to make advanced cancer diagnostics more accessible worldwide. This could potentially lead to improved patient outcomes across diverse healthcare systems and geographical regions 1.
Addressing the Pathologist Shortage
One of the key challenges this partnership seeks to address is the global shortage of pathologists. With the increasing incidence of cancer worldwide, the demand for skilled pathologists has outpaced the available workforce. The AI-powered solutions developed through this collaboration could help bridge this gap by augmenting the capabilities of existing pathologists and potentially reducing the workload on these specialists 2.
Future Implications for Cancer Care
The Roche-Qritive partnership represents a significant step towards the digitalization and automation of cancer diagnostics. By harnessing the power of AI, this collaboration has the potential to not only improve the speed and accuracy of diagnoses but also to standardize diagnostic processes across different healthcare settings. This could lead to more consistent and reliable cancer diagnoses, ultimately contributing to better treatment planning and patient care 1 2.
Roche Expands Digital Pathology Open Environment to Advance AI-Driven Cancer Diagnostics
Roche has announced the expansion of its Digital Pathology Open Environment, integrating AI-powered tools from third-party developers to enhance cancer diagnostics and improve patient care.
2 Sources
2 Sources
GE HealthCare and DeepHealth Collaborate to Advance AI-Powered Breast Cancer Screening
GE HealthCare and DeepHealth, a RadNet subsidiary, join forces to develop AI-driven solutions for breast cancer screening, aiming to improve early detection and streamline workflows.
2 Sources
2 Sources
QDX and Prelude Therapeutics Collaborate on Novel Oncology Programs
QDX Technology and Prelude Therapeutics have announced a collaboration to develop novel oncology programs. The partnership aims to leverage QDX's AI-driven drug discovery platform to accelerate Prelude's cancer drug development efforts.
2 Sources
2 Sources
Qure.ai Secures $65 Million in Funding to Advance AI-Driven Medical Diagnostics
Mumbai-based startup Qure.ai has raised $65 million in a funding round led by Lightspeed Venture Partners. The company aims to accelerate the development of AI-powered medical diagnosis tools and expand its global presence.
5 Sources
5 Sources
SOPHiA GENETICS Showcases Advancements in Cancer Care at ESMO 2024
SOPHiA GENETICS announces updates on its SOPHiA UNITY platform and poster presentations at the European Society for Medical Oncology (ESMO) 2024 Congress, highlighting progress in precision medicine for cancer treatment.
2 Sources
2 Sources
Your one-stop AI hub
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
The Outpost
Keep in touch
© 2025 TheOutpost.AI All rights reserved